<DOC>
	<DOCNO>NCT02052908</DOCNO>
	<brief_summary>This randomized phase Ib trial study side effect best dose naproxen prevent deoxyribonucleic acid ( DNA ) mismatch repair deficient colorectal cancer patient Lynch syndrome . Chemoprevention use certain drug keep cancer forming . The use naproxen may keep cancer form patient Lynch syndrome .</brief_summary>
	<brief_title>Naproxen Preventing DNA Mismatch Repair Deficient Colorectal Cancer Patients With Lynch Syndrome</brief_title>
	<detailed_description>PRIMARY OBJECTIVES : I . To determine whether treatment naproxen once-daily 220 mg 440-mg dose , administer 6 month compare placebo reduces concentration prostaglandin E2 ( PGE2 ) level normal colorectal mucosa subject risk mismatch repair deficient colorectal cancer . II . To determine toxicity profile tolerability naproxen two dos ( 220 mg 440-mg daily ) compare placebo 6 month therapy subject risk mismatch repair deficient colorectal cancer . SECONDARY OBJECTIVES : I . To determine naproxen concentration plasma patient risk DNA mismatch repair deficient colorectal cancer take naproxen daily , 220 mg , 440 mg placebo 6 month therapy compare baseline level . II . To determine naproxen concentration normal colorectal mucosa patient risk DNA mismatch repair deficient colorectal cancer ( CRC ) take naproxen daily 220 mg , 440 mg placebo 6 month therapy compare baseline level . III . To determine whether urinary prostaglandin-endoperoxide synthase 1 metabolite ( PGE-M ) significantly high patient risk DNA mismatch repair deficient CRC take naproxen one daily , 220 mg , 440 mg placebo 6 month therapy compare baseline level . IV . To determine whether 6-months therapy naproxen daily , 220 mg , 440 mg placebo lead reduction number polyp observe rectosigmoid rectal area . V. To determine whether naproxen daily , 220 mg , 440 mg placebo significantly change micro-ribonucleic ( RNA ) profile normal colorectal mucosa patient risk DNA mismatch repair deficient CRC compare baseline . VI . To determine whether naproxen daily , 220 mg , 440 mg placebo significantly change gene expression messenger RNA ( mRNA ) profile normal colorectal mucosa patient risk DNA mismatch repair deficient CRC compare baseline . VII . To determine whether naproxen daily , 220 mg , 440 mg placebo significantly change mutational rate patient risk DNA mismatch repair deficient CRC compare placebo . VIII . To determine future candidate biomarkers measure genomic transcriptomic platform tissue biopsy normal colorectal mucosa individual risk mismatch repair deficient CRC pre- post-treatment naproxen . OUTLINE : Patients randomize 1 3 treatment arm . ARM I : Patients receive high-dose naproxen orally ( PO ) daily ( QD ) 6 month . ARM II : Patients receive low-dose naproxen PO QD placebo PO QD 6 month . ARM III : Patients receive placebo PO QD 6 month . After completion study treatment , patient follow 2 week .</detailed_description>
	<mesh_term>Syndrome</mesh_term>
	<mesh_term>Colorectal Neoplasms</mesh_term>
	<mesh_term>Colorectal Neoplasms , Hereditary Nonpolyposis</mesh_term>
	<mesh_term>Naproxen</mesh_term>
	<criteria>Participants must Lynch syndrome defined meeting following : `` Mutationpositive Lynch syndrome '' : carrier obligate carrier ( pedigree ) pathogenic mutation one DNA mismatch repair ( MMR ) gene ( i.e . mutL homolog 1 [ MLH1 ] , mutS homolog 2 [ MSH2 ] /epithelial cell adhesion molecule [ EPCAM ] , mutS homolog 6 [ MSH6 ] , PMS2 postmeiotic segregation increase 2 [ S. cerevisiae ] [ PMS2 ] ) `` Mutationnegative Lynch syndrome '' : patient personal history nonsporadic MMR deficient premalignant lesion ( i.e . polyp ) nonsporadic MMR deficient malignant tumor ( `` nonsporadic MMR deficient '' define : microsatelliteinstability high either immunohistochemistry microsatellite instability [ MSI ] testing , evidence MLH1 promoter methylation case loss MLH1 PMS2 , and/or evidence vraf murine sarcoma viral oncogene homolog B [ BRAF ] mutation case loss MLH1 PMS2 ) germline MMR genetic testing show either variant unknown significance mutation negative result decline germline MMR genetic testing Participants must evidence active/recurrent malignant disease 6 month Participants must least 6 month prior cancerdirected treatment ( surgical resection , chemotherapy , immunotherapy , hormonal therapy radiation ) Participants must endoscopically accessible distal colon and/or rectal mucosa ( i.e . participant must least part descending/sigmoid colon and/or rectum intact ) Participants must consent one standard care lower gastrointestinal ( GI ) endoscopy ( flexible sigmoidoscopy colonoscopy ) biopsies one flexible sigmoidoscopy biopsy 6 month ( +14 day ) apart Participants must consent refrain use aspirin nonsteroidal antiinflammatory drug ( NSAIDs ) cyclooxygenase ( COX ) inhibitor duration trial Eastern Cooperative Oncology Group ( ECOG ) performance status = &lt; 1 ( Karnofsky &gt; = 70 % ) Hemoglobin &gt; = 10 g/dL hematocrit &gt; = 30 % Leukocyte count &gt; = 3,000/microliter Platelet count &gt; = 100,000/microliter Absolute neutrophil count &gt; = 1,500/microliter Creatinine = &lt; 1.5 x institutional upper limit normal ( ULN ) ( OR glomerular filtration rate [ GFR ] &gt; 30 ml/min/1.73 m^2 ) Total bilirubin = &lt; 2 x institutional ULN Aspartate aminotransferase ( AST ) ( serum glutamic oxaloacetic transaminase [ SGOT ] ) = &lt; 2.5 × institutional ULN Alanine aminotransferase ( ALT ) ( serum glutamate pyruvate transaminase [ SGPT ] ) = &lt; 2.5 × institutional ULN Women childbearing potential must agree use adequate contraception ( hormonal barrier method birth control ; abstinence ) duration study participation ; woman become pregnant suspect pregnant time study entry participate study , inform study physician immediately ; woman childbearing potential must agree baseline predrug pregnancy test Ability understand willingness sign write informed consent document Individuals receive schedule aspirin , NSAIDs , COXinhibitors kind 3 day ( &gt; 3 day ) anytime within 2 week precede baseline eligibility screen visit ; individual cardioprotective aspirin eligible Individuals status post total proctocolectomy ( i.e . removal colon rectum ) Individuals active gastroduodenal ulcer disease precede 5 year Individuals history transfusiondependent gastrointestinal bleeding , gastrointestinal perforation gastrointestinal obstruction ; event due malignancy GI tract malignancy since remove , patient eligible Individuals history myocardial infarction , stroke , coronaryartery bypass draft , invasive coronary revascularization precede 5 year Individuals take drug list may randomize unless willing stop medication ( possibly change alternative nonexcluded medication treat condition ) less 7 day prior start naproxen placebo study ; consultation participant 's primary care provider may obtain require ; use follow drug drug class prohibit naproxen/placebo treatment : Investigational agent NSAIDs : aspirin , ketorolac others NSAIDs COX2 inhibitor : celecoxib , rofecoxib COX2 Antiplatelet agent : aspirin , clopidogrel , ticlopidine , dipyridamole , abciximab , tirofiban , eptifibatide prasugrel Anticoagulants : Heparin Heparinoids : fondaparinux , danaparoid heparinoids Lowmolecular weight heparin : enoxaparin , dalteparin , parnaparin , reviparin , tinzaparin , ardeparin , certoparin , lepirudin , bivalirudin Other anticoagulant : argatroban , apixaban , dabigatran , rivaroxaban , warfarin , acenocoumarol , dicumarol , phenindione anticoagulant Lithium Selective serotonin norepinephrine reuptake inhibitor : milnacipran , fluoxetine , paroxetine , nefazodone , citalopram , clovoxamine , escitalopram , flesinoxan , femoxetine , duloxetine , venlafaxine , vilazodone , sibutramine , desvenlafaxine Anticonvulsants : phenytoin , paraldehyde , valproic acid , carbamazepine , trimethadione , phenobarbital , diazepam , chlormethiazole , mephenytoin , ethotoin , paramethadione , phenacemide , mephobarbital , oxcarbazepine , zonisamide , piracetam , vigabatrin , felbamate , gabapentin , beclamide , fosphenytoin , stiripentol , tiagabine , topiramate , pregabalin , lacosamide , rufinamide , caramiphen Antibiotics antifungal : Fluoroquinolones : ofloxacin , norfloxacin , levofloxacin Other agent : teriflunomide , cyclosporine , tacrolimus , ginkgo , gossypol , meadowsweet , feverfew , beta glucan , pentosan , pentoxifylline , cilostazol , erlotinib , pemetrexed , methotrexate , pralatrexate Individuals uncontrolled renal insufficiency renal failure History allergic reaction attribute naproxen Uncontrolled intercurrent illness include , limited , ongoing active infection , uncontrolled hypertension , symptomatic congestive heart failure , unstable angina pectoris , cardiac arrhythmia , psychiatric illness/social situation would limit compliance study requirement Pregnant , breastfeeding , woman childbearing potential unwilling use reliable contraceptive method ; pregnant woman exclude study ; breastfeed discontinue mother treated naproxen</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>November 2016</verification_date>
</DOC>